United Nations & Moderna

United Nations: Leading the international response coordination, warning of exponential growth and calling for more funding. Its credibility is tied to the effectiveness of the response.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

United Nations: The United Nations released $60 million from its Central Emergency Response Fund to accelerate the response to the Ebola outbreak in the region, providing crucial financial support.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

United Nations: The United Nations released $60 million from its Central Emergency Response Fund to accelerate the Ebola response in the Democratic Republic of the Congo and the region.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

United Nations: The United Nations>>> has mobilized emergency support and released funds to accelerate the Ebola response in the Democratic Republic of the Congo>>> and the region, providing logistical assistance and aid.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

United Nations: The United Nations is coordinating the response and warning of exponential spread, highlighting the severity of the outbreak. Its role is crucial in mobilizing international support.

Moderna: Moderna is developing an mRNA-based vaccine targeting the Bundibugyo strain, currently in clinical trials. Its progress could offer a more specific solution and enhance its vaccine portfolio.

United Nations: Highlighting the shadow crisis of rising maternal deaths as pregnant women avoid hospitals. Its data underscores the indirect health impacts of the outbreak.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

United Nations: The United Nations humanitarian office reported that almost a million people have been displaced from their homes by conflict in Democratic Republic of the Congo — Ituri Province, contributing to the challenges of the Ebola response.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.